TEK and neoplasm: Targeting the receptor tyrosine kinases vascular endothelial growth factor receptor (VEGFR) 1 to 3, angiopoietin-1 receptor (TIE2), and platelet-derived growth factor receptor (PDGFR) β, regorafenib inhibits tumor neovascularization and vessel stabilization [10].